First-in-Human Dose Expansion Study of XMT-1536 in Cancers Likely to Express NaPi2b
Clinical trial NCT06517485 · COMPLETED
Trial details
- NCT number
- NCT06517485
- Sponsor
- Mersana Therapeutics
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2019-07-30
- Primary completion
- 2022-05-31
- Enrollment
- 142
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.